Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sanofi (US Rights for 5 branded pharmaceuticals)

M&A STATUS
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portfolio of five branded pharmaceuticals. The five branded pharmaceuticals include Nilandron, Plaquenil, Rilutek, Uroxatral and Kayexalate.

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Other Business Products and Services
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 54, rue La Boétie
  • 75008 Paris
  • France

Sanofi (US Rights for 5 branded pharmaceuticals) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sanofi (US Rights for 5 branded pharmaceuticals)‘s full profile, request access.

Request full access to PitchBook

Sanofi (US Rights for 5 branded pharmaceuticals) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sanofi (US Rights for 5 branded pharmaceuticals)‘s full profile, request access.

Request full access to PitchBook